BACKGROUND AND PURPOSE: Recent evidence suggests that variation in the SNCA, MAPT, and GSK3B genes interacts in affecting risk for Parkinson disease (PD). In the current study, we attempt to validate previously published findings, evaluating gene-gene interactions between SNCA, MAPT, and GSK3B in association with PD. METHODS: Three Caucasian PD patient-control series from the United States, Ireland, and Norway (combined n = 1020 patients and 1095 controls) were genotyped for SNCA rs356219, MAPT H1/H2-discriminating SNP rs1052553, and GSK3B rs334558 and rs6438552. RESULTS: Our findings indicate that as previously reported, the SNCA rs356219-G allele and MAPT rs1052553 (H1 haplotype) were both associated with an increased risk of PD, whilst contrary to previous reports, GSK3B variants were not. No pair-wise interaction was observed between SNCA, MAPT, and GSK3B; the risk effects of SNCA rs356219-G and MAPT rs1052553-H1 were seen in a similar manner across genotypes of other variants, with no evidence suggesting synergistic, antagonistic, or deferential effects. CONCLUSIONS: In the Caucasian patient-control series examined, risk for PD was influenced by variation in SNCA and MAPT but not GSK3B. Additionally, those three genes did not interact in determining disease risk.
BACKGROUND AND PURPOSE: Recent evidence suggests that variation in the SNCA, MAPT, and GSK3B genes interacts in affecting risk for Parkinson disease (PD). In the current study, we attempt to validate previously published findings, evaluating gene-gene interactions between SNCA, MAPT, and GSK3B in association with PD. METHODS: Three Caucasian PDpatient-control series from the United States, Ireland, and Norway (combined n = 1020 patients and 1095 controls) were genotyped for SNCArs356219, MAPT H1/H2-discriminating SNP rs1052553, and GSK3Brs334558 and rs6438552. RESULTS: Our findings indicate that as previously reported, the SNCArs356219-G allele and MAPTrs1052553 (H1 haplotype) were both associated with an increased risk of PD, whilst contrary to previous reports, GSK3B variants were not. No pair-wise interaction was observed between SNCA, MAPT, and GSK3B; the risk effects of SNCArs356219-G and MAPTrs1052553-H1 were seen in a similar manner across genotypes of other variants, with no evidence suggesting synergistic, antagonistic, or deferential effects. CONCLUSIONS: In the Caucasian patient-control series examined, risk for PD was influenced by variation in SNCA and MAPT but not GSK3B. Additionally, those three genes did not interact in determining disease risk.
Authors: J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu Journal: Cell Death Differ Date: 2014-11-14 Impact factor: 15.828
Authors: Angela Roco; Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Carmen Martínez; Martín Zurdo; Laura Turpín-Fenoll; Jorge Millán; Teresa Adeva-Bartolomé; Esther Cubo; Francisco Navacerrada; Ana Rojo-Sebastián; Lluisa Rubio; Marisol Calleja; José Francisco Plaza-Nieto; Belén Pilo-de-la-Fuente; Margarita Arroyo-Solera; Elena García-Martín; José A G Agúndez Journal: J Neural Transm (Vienna) Date: 2012-09-22 Impact factor: 3.575
Authors: Michael G Heckman; Alexis Elbaz; Alexandra I Soto-Ortolaza; Daniel J Serie; Jan O Aasly; Grazia Annesi; Georg Auburger; Justin A Bacon; Magdalena Boczarska-Jedynak; Maria Bozi; Laura Brighina; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Alain Destée; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; Suzana Gispert; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Chin-Hsien Lin; Katja Lohmann; Marie-Anne Loriot; Timothy Lynch; George D Mellick; Eugénie Mutez; Grzegorz Opala; Sung Sup Park; Simona Petrucci; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Georgia Xiromerisiou; Demetrius M Maraganore; Matthew J Farrer; Owen A Ross Journal: Neurobiol Aging Date: 2013-08-17 Impact factor: 4.673
Authors: Mariet Allen; Fanggeng Zou; High Seng Chai; Curtis S Younkin; Richard Miles; Asha A Nair; Julia E Crook; V Shane Pankratz; Minerva M Carrasquillo; Christopher N Rowley; Thuy Nguyen; Li Ma; Kimberly G Malphrus; Gina Bisceglio; Alexandra I Ortolaza; Ryan Palusak; Sumit Middha; Sooraj Maharjan; Constantin Georgescu; Debra Schultz; Fariborz Rakhshan; Christopher P Kolbert; Jin Jen; Sigrid B Sando; Jan O Aasly; Maria Barcikowska; Ryan J Uitti; Zbigniew K Wszolek; Owen A Ross; Ronald C Petersen; Neill R Graff-Radford; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner Journal: Mol Neurodegener Date: 2012-04-11 Impact factor: 14.195
Authors: Simon Moussaud; Daryl R Jones; Elisabeth L Moussaud-Lamodière; Marion Delenclos; Owen A Ross; Pamela J McLean Journal: Mol Neurodegener Date: 2014-10-29 Impact factor: 14.195
Authors: Elena García-Martín; Carmen Martínez; Hortensia Alonso-Navarro; Julián Benito-León; Oswaldo Lorenzo-Betancor; Pau Pastor; Tomás López-Alburquerque; Lluis Samaranch; Elena Lorenzo; José A G Agúndez; Félix Javier Jiménez-Jiménez Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240